Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Of mice and men: converging on a common molecular understanding of osteoarthritis

Tonia L Vincent

Despite an increasing burden of osteoarthritis in developed societies, target discovery has been slow and there are currently no approved disease-modifying osteoarthritis drugs. This lack of progress is due in part to a series of misconceptions over the years: that osteoarthritis is an inevitable consequence of ageing, that damaged articular cartilage cannot heal itself, and that osteoarthritis is driven by synovial inflammation similar to that seen in rheumatoid arthritis. Molecular interrogation of disease through ex-vivo tissue analysis, in-vitro studies, and preclinical models have radically reshaped the knowledge landscape. Inflammation in osteoarthritis appears to be distinct from that seen in rheumatoid arthritis. Recent randomised controlled trials, using treatments repurposed from rheumatoid arthritis, have largely been unsuccessful. Genome-wide studies point to defects in repair pathways, which accords well with recent promise using growth factor therapies or Wnt pathway antagonism. Nerve growth factor has emerged as a robust target in osteoarthritis pain in phase 2–3 trials. These studies, both positive and negative, align well with those in preclinical surgical models of osteoarthritis, indicating that pathogenic mechanisms identified in mice can lead researchers to valid human targets. Several novel candidate pathways are emerging from preclinical studies that offer hope of future translational impact. Enhancing trust between industry, basic, and clinical scientists will optimise our collective chance of success.

Introduction

The global impact of osteoarthritis, the most common form of joint disease in developed societies, is predicted to rise steadily as obesity and longevity increase.1 Osteoarthritis is a substantial societal burden, associated with increased morbidity and frequently complicated by multimorbidity and polypharmacy.12 The recent acceptance of osteoarthritis as a serious disease has helped to drive the therapeutic agenda forward, to garner support from academia and industry, and to influence health-care prioritisation.13 The market for symptomatic and disease-modifying treatments is huge, and yet relatively little progress has been made thus far in bringing new treatments to patients.

Osteoarthritis research can be broadly divided into clinical and basic categories. Clinical research includes pathology, epidemiology, and interventional studies in humans, whereas basic research encompasses the study of molecular pathogenesis through in-vitro systems, preclinical models, and large-scale omics (ie, genomics, transcriptomics, proteomics, and metabolomics) studies. Osteoarthritis is a mechanically driven disease. This notion is compellingly described in the epidemiological literature6 and confirmed in basic science studies, which have shown the highly mechanosensitive nature of joint tissues,7–10 the activation of inflammatory signalling by mechanical injury,11,12 the dependence on mechanics in preclinical osteoarthritis,13,14 and the involvement of mechanosensing mechanisms in in-vivo pathogenesis.15 Several other important causal factors—such as obesity, age, and genetics—affect the ability of joint tissues to withstand mechanical stress over a lifetime and affect the ability to repair damaged tissues. These factors might also increase the risk of osteoarthritis in ways that are independent of mechanics. For example, osteoarthritis in non-weightbearing joints is increased in obese individuals,16 possibly due to low-grade systemic inflammation,19,20 which might be linked to the gut microbiome.21 Various impediments are recognised in osteoarthritis drug development. Osteoarthritis is an insidious and heterogeneous disease. These qualities inevitably mean that clinical trials are often prohibitively expensive, and raise the possibility that one target might not work for all. Molecular pathogenesis also has its challenges. Molecular tools have needed to be refined to work in paucicellular, matrix-rich tissues, such as articular cartilage. Low access to human tissue at early stages of disease has necessitated a reliance on preclinical models, which has also required substantial refinement, largely involving moving away from disease models involving chemical induction methods (eg, monosodium iodoacetate, papain, and collagenase injection) in favour of those induced by surgical destabilisation of the joint.22 In the past 15 years, target discovery in osteoarthritis has increased substantially, particularly through large, agnostic omic studies using end-stage human disease tissue and through molecular validation facilitated by preclinical mouse models and clinical trials. There has also been considerable research into methodological tools for improving clinical outcome measures and osteoarthritis trial design.23 In this Review, recent successes and failures in osteoarthritis clinical trials are considered in parallel with preclinical advances. Together, these different types of research are helping to unravel the complexities of osteoarthritis pathogenesis and to provide future targeting strategies with a higher chance of translational success.

Targeting inflammation in osteoarthritis

Support for the involvement of inflammation in osteoarthritis comes from clinical observation (joint line tenderness, synovial thickening, and episodic joint effusion) and radiographic evidence of synovial hypertrophy and bone...
marrow oedema (by MRI and ultrasound) that are associated with clinical outcome. Additionally, various inflammatory molecules—including cytokines, chemokines, and metalloproteinases—have been measured in osteoarthritis cartilage and synovium.

Clinicians distinguish between inflammatory arthritis and osteoarthritis through a relative paucity of leucocytes in osteoarthritis synovial fluid, which are predominantly monocytes (in osteoarthritis) rather than neutrophils (in rheumatoid arthritis). Patients with osteoarthritis typically complain of less than 30 min early morning stiffness and show a modest systemic inflammatory response. These features are used clinically to aid the diagnosis of osteoarthritis. Whether low-grade inflammation contributes to osteoarthritis pathogenesis, both in terms of pain and structural disease, has been subject to heated debate over the years. Several randomised controlled trials that address different aspects of inflammation have been recently conducted. All the tested drugs derive from experience in rheumatoid arthritis where there is proven efficacy for such therapies.

**Corticosteroids**

Intra-articular corticosteroids are widely used in clinical practice in osteoarthritis, although few historical studies have applied stringent placebo-controlled, randomised, and double-blind assessments. In hand osteoarthritis, a randomised controlled trial of intra-articular triamcinolone hexacetonide (a long-acting steroid preparation) plus lidocaine (a local anaesthetic) showed clinical improvement up to 12 weeks following injection of the drug compared with lidocaine alone. This result met the primary outcome of the study, albeit in only two of eight co-primary endpoints. For both groups, the injected joint was splinted for 48 h immediately after treatment. A phase 2b trial of an extended-release intra-articular steroid showed greater efficacy than placebo in pain outcomes for knee osteoarthritis at several time points, even though the primary endpoint (pain at 12 weeks) was not met. Combined phase 2–3 studies of this preparation have showed an acceptable safety profile and a reduction in synovial thickness, but no improvement in synovitis by MRI or power doppler assessment, making the primary target tissue of the drug unclear.

Few studies have attempted to examine the long-term effects of corticosteroids on joints. In a randomised controlled trial by McAlindon and colleagues, 140 patients with knee osteoarthritis were randomly assigned to receive intra-articular injections of triamcinolone or saline once every 3 months for 2 years. Clinical outcomes were assessed every 3 months, and cartilage damage was measured by MRI at 2 years. No clinical benefit was seen for any of the outcome measures compared with placebo, although it is possible that the periodicity of follow-up caused transient responses to be missed (ie, if responses returned to baseline by 3 months). Importantly, this study showed a small but statistically significant increase in cartilage volume loss, raising concerns about the effect of repeated and long-term corticosteroid use on joint health.

Similar findings were also shown using data derived from the Osteoarthritis Initiative. A cautious approach to intra-articular steroid is indicated by a “conditional type 1B recommendation” for this treatment in the 2019 guidelines from the Osteoarthritis Research Society International for non-surgical treatment of hip and knee osteoarthritis.

**Disease-modifying anti-rheumatic drugs**

Both hydroxychloroquine and methotrexate are used in patients with rheumatoid arthritis and, less commonly, on an individual-patient basis in osteoarthritis. Two randomised controlled trials using oral hydroxychloroquine in hand osteoarthritis have been published, neither of which met the primary study endpoint of reduction in pain. No clinical response was seen in a predefined substudy in which patients were stratified by the presence or absence of power doppler signal, which is indicative of a more inflammatory phenotype. The PROMOTE study has reported by abstract a small difference in pain in those with knee osteoarthritis taking methotrexate, although the effect size was not deemed clinically meaningful. A small randomised controlled trial of 64 patients with hand osteoarthritis taking 10 mg of methotrexate failed to show a beneficial effect on pain, the primary outcome, although some changes to the evolution of joint remodelling were suggested in the reported abstract. A meta-analysis has concluded no efficacy of conventional synthetic disease-modifying anti-rheumatic drugs across all joint osteoarthritis.

**Anticytokine therapies**

An absence of efficacy was also evident in four randomised controlled trials in hand osteoarthritis that targeted either tumour necrosis factor or interleukin (IL)-1. One of two trials in knee osteoarthritis targeting IL-1, one of which used an intra-articular approach. Despite promise from various small open-label studies, none of the randomised controlled trials met their primary study endpoints, suggesting that classical cytokine-driven inflammation is
at the root of neither pain nor structural damage in osteoarthritis. These results are in accordance with preclinical data in which gene deletion of IL-1β,
the IL-1 converting enzyme, IL-1R (Vincent, unpublished data), tumour necrosis factor, or inflammasome pathway components (which lead to processing of IL-1 family cytokines) does not confer protection from osteoarthritis after surgical joint destabilisation. Despite a strong rationale based on in-vitro studies, evidence to support a direct pathogenic role for IL-1 in osteoarthritis pathogenesis appears, in retrospect, to have been weak.

**Other putative inflammatory targets from preclinical models**

These studies force us to conclude that classical inflammation, of the type that is pathogenic in rheumatoid arthritis, does not drive osteoarthritis. One exception to this notion might be IL-6. Although the osteoarthritis phenotype has been inconsistently reported in IL-6 knockout mice, therapeutic studies suggest that neutralisation of IL-6 modifies disease in murine osteoarthritis. A clinical trial using tocilizumab, an IL-6 receptor-neutralising antibody, in hand osteoarthritis completed in 2019 but has not yet been reported (registered with ClinicalTrials.gov, NCT03595618).

Targeting the proteases that degrade the articular cartilage extracellular matrix has long been regarded as an attractive approach to disease modification in osteoarthritis. A disintegrin and metalloproteinase with thrombospondin motif (Adamts)-5 was identified as the principal aggrecan-degrading enzyme in mice, and in humans ADAMTS-5 also mediates proteolytic activity in osteoarthritic chondrocytes (possibly also involving ADAMTS-4). Aggrecanase inhibition is being re-explored, after companies had abandoned earlier studies at the preclinical phase because of adverse cardiovascular events, using an anti-Adamts-5 monoclonal antibody. A good safety profile and evidence of target engagement with a small molecule inhibitor is now being followed by phase 2 studies in knee osteoarthritis, with structural disease as the primary outcome (registered with ClinicalTrials.gov, NCT03595618).

Activation of other components of the innate immune system might have more important pathogenic roles in disease, and some of these components have been examined in preclinical osteoarthritis (table 1). Several chemokine family members have been explored after joint destabilisation, with some having disease-modifying effects in murine osteoarthritis (table 1). These proteins are expressed by chondrocytes and have chondroprotective and disease-causing roles, not always correlating with cell infiltration of the joint. They therefore probably act in both canonical and non-canonical ways. C-C motif chemokine 2 (Ccl2) and its receptor, C-C chemokine receptor type 2 (Ccr2), are the best validated of these targets.

| Complement | Target tested | Study details | Cartilage modifying? | Symptom modifying? |
|-------------|---------------|---------------|----------------------|--------------------|
| Wang et al | C5 and C659a | Knockout data confirmed by pharmacological approach | Yes | Not examined |

| Chemokines | |
|-------------| |
| Miotla Zarebska et al | Ccl2 or Cx2 | Constitutive gene deletion inconsistent across different studies but appearing to show structure modification at later time points; pharmacological studies point towards a key treatment window | Inconsistent | Yes |
| Miller et al, Raghu et al, and Appleton et al | Cxcr5 or Ccl5 | Inconsistent cartilage degradation scores; neither study showed a difference in synovitis scores after gene deletion | Inconsistent | Not examined |
| Takebe et al and Raghu et al | Cxcr5 or Ccl5 | | |
| Sambaranurthy et al | Cxc2 | | |
| Sherwood et al | | | |
| Qin et al | Ccr4 | Inhibition in bone abrogates surgically induced osteoarthritis | Yes | Not examined |

| Mechanoflammation | |
|--------------------| |
| Choi et al | Il6-1βa subunit of Il1b | Over-expression worsens disease; conditional detection leads to decreased disease (both on Ccl2 promoter) | Yes | Not examined |
| Kobayashi et al | RelA (p65) Nf-κB transcription factor | Dual action of RelA in disease: heterozygotes protected, homozygotes showed increased disease through prevention of anti-apoptotic mechanisms induced by Pik3r1 (a Gwas hit for cartilage thickness) | Yes | Not examined |
| Culley et al | Ilkα | Conditional knockout (aggrecan Cre) disease protection associated with increased apoptosis | Yes | Not examined |
| Ismael et al | Jnk2 | Chondroprotection observed at 4 weeks, 8 weeks, and 12 weeks after surgery | Yes | Not examined |

| Mast-cell activation | |
|----------------------| |
| Wang et al | C-Kit and Mc1 | Deletion produces functional deletion of C-Kit-dependent and -independent mast cells; chondroprotection also observed with Apc366, a tryptase inhibitor | Yes | Not examined |
| Wang et al | Igh7 and Fcer1 | Both genes target IgE-mediated activation of mast cells, indicating that IgE-induced mast-cell activation drives osteoarthritis pathology | Yes | Not examined |

Table 1: Putative innate immune targets showing disease modification in preclinical studies
Constitutive deletion of Ccl2 or Ccr2 delays and suppresses pain severity in preclinical osteoarthritis but has little effect on cartilage damage when induced in animals that are 10 weeks old. However, a reduction in structural disease has been seen when older (aged 20 weeks) Ccr2 knockout mice are subjected to joint destabilisation, and when pharmacological Ccr2 inhibition is delivered. In another study, structure modification was observed when a Ccr2 antagonist was given either between 1-4 or 4-8 weeks after joint destabilisation, but not when given between 8–12 or 1–8 weeks after. A reduction in pain behaviour was observed over short (3 week) and long (12 week) periods of treatment at all stages of disease. Blocking transforming growth factor α (Tgfn) signalling, a strong inducer of Ccl2 in the rodent osteoarthritis joint, also reduced structural disease after joint destabilisation in the rat. TGFα is of particular interest because it has been identified as a candidate gene for determining cartilage thickness and osteoarthritis risk in humans. These results point towards a role for Ccl2 and Ccr2 in murine osteoarthritis pain and a possible role in structural progression.

Two mRNA studies of human synovium have been done in individuals stratified by having painful or non-painful osteoarthritis. One of these studies identified CCL2 as being significantly up-regulated in painful disease. CCR2 antagonism in osteoarthritis pain has been explored clinically (registered with ClinicalTrials.gov, NCT00689273), although the results of the study do not appear to have been reported. A clinical study examining TGFα blockade is currently recruiting (registered with ClinicalTrials.gov, NCT04456686). All current osteoarthritis disease-modifying drug trials are summarised in table 2.

Other types of innate immune activation might be important in osteoarthritis pathogenesis but have as yet only been explored as targets in preclinical models (table 1). Components of the common terminal pathway of complement activation are strongly up-regulated in the synovial fluid of individuals with osteoarthritis, with evidence of the formation of membrane attack complex within human osteoarthritis cartilage. Deletion of C5 (an upstream activator of the common pathway) in mice led to reduced disease severity after joint destabilisation, whereas deletion of an inhibitor of terminal activation (Cdf59a) led to increased disease severity. The same research group also identified mast-cell activity as a pathogenic mediator in murine osteoarthritis. Mast-cell activation has previously been described in the osteoarthritis joint, and is associated with structural disease.

Inflammasome activation is purported to have a role in osteoarthritis, especially when disease is complicated by a crystal arthropathy. However, studies in mice in which components of the inflammasome pathway (activated by crystals) were genetically deleted failed to show a role for inflammasome in surgically induced osteoarthritis. Several groups have examined the role of alarmins in osteoarthritis, through deletion of Toll-like receptors, $100$ proteins, or advanced glycosylation end product-specific receptors. Collectively, these studies do not support a role for these molecules in surgically induced murine osteoarthritis.

Many preclinical studies in this area of research remain unpublished, and this reporting bias has been unhelpful for research over the years.

My own work, and work arising from the Centre of Osteoarthritis Pathogenesis at the Kennedy Institute of Rheumatology (Oxford, UK) has highlighted an important role for what has been termed mechanoflammation, showing that mechanical injury directly drives inflammatory signalling and inflammatory genes in joint tissues, including the articular cartilage and synovium. Joint immobilisation after destabilisation surgery attenuates the induction of pathogenic proteases and prevents osteoarthritis development. Mechanoflammation drives TGFβ-activated kinase (TAK1) and downstream activation of the inflammatory mitogen-activated protein kinases (JNK and p38) and nuclear factor κB (NF-κB). NF-κB signalling pathway has long been considered an important inducer of inflammatory gene regulation in osteoarthritis. It is a complex pathway with canonical and non-canonical pathways that mediate anti-apoptotic and pro-inflammatory functions. This characterisation has been confirmed in vivo in a dose-dependent manner, in which heterozygous deletion of RelA (p65), a transcription factor activated upon canonical NF-κB activation, resulted in chondroprotection, whereas homozygous deletion led to accelerated disease through the suppression of apoptosis. Accelerated disease resulting from homozygous deletion of p65 was mediated through decreased expression of the anti-apoptotic gene Pik3r1, itself a candidate gene arising from a genome-wide association study for cartilage thickness. Deletion of Ikκα (which inhibits κB-kinase-α, an upstream NF-κB pathway activator) leads to disease protection and anti-apoptotic effects in vivo. Although NF-κB might be important in transcriptional regulation of proteases in osteoarthritis, JNK activation controls the bioavailability of aggrecanase activity in vitro and in vivo, by a mechanism that appears to involve re-uptake of aggrecanases by the cell surface scavenger receptor, low-density lipoprotein receptor-related protein. Targeting protease activity through metal cation symporter Zip8, a zinc transporter, has also been shown in murine osteoarthritis. Zip8 is regulated by the hypoxia transcription factor Hif2α, which has also been shown to be disease-modifying in preclinical osteoarthritis models.

Promoting anabolism and repair in osteoarthritis

The inability of articular cartilage to repair is famously attributed to William Hunter who stated in 1743 that “...ulcerated Cartilage is universally allowed to be a very troublesome disease...and when destroyed, it is never recovered.” The essence of this statement has been reiterated in textbooks for decades, but recent years have seen a paradigm shift. Improved MRI imaging indicates that asymptomatic focal defects in the joint surface are much more common than previously suggested, and prospective studies conclude that around 30% of focal
### Registered active drug trials in osteoarthritis

| Study type and number of participants | Drug | Target or drug type | Route | Trial status | Primary outcome | Secondary outcomes |
|--------------------------------------|------|---------------------|-------|--------------|----------------|-------------------|
| Phase 2 randomised controlled trial; 125 participants | LY3016859 | Transforming growth factor α and epiregulin | Intravenous | Recruiting | Pain (numeric rating scale) | Function |
| Phase 1 randomised controlled trial; 24 participants | PPV-06 vaccination | Interleukin-6 | Subcutaneous | Not yet recruiting | Safety | Not given |
| Phase 3 randomised controlled trial; 726 participants | Lorecivint (SM04690) | Wnt pathway | Intr-aortic | Recruiting | Pain (numeric rating scale) | Function |
| Phase 3 randomised controlled trial; 128 participants | Diacerein | Unknown or anti-inflammatory | Oral | Not yet recruiting | Structure (MRI) | Function |
| Phase 3 randomised controlled trial; 70 participants | Zoledronic acid | Osteoclast activity | Intravenous | Recruiting | Pain (Visual analogue scale) | Function; structure |
| Phase 3 randomised controlled trial; 231 participants | Cingal | Triamcinolone plus hyaluronate | Intr-aortic | Not yet recruiting | Pain (WOMAC) | Not given |
| Phase 2 crossover controlled trial; 40 participants | Duloxetine | CNS reuptake inhibitor | Oral | Recruiting | Pressure pain threshold | Not given |
| Phase 4 randomised open-label trial; 150 participants | Duloxetine plus hyaluronate | CNS reuptake inhibitor plus corticosteroid plus hyaluronan | Oral and intra-articular | Not yet recruiting | Pain (average pain scores) | Function |
| Open-label trial; 35 participants | Zilretta | Corticosteroid (slow release) | Intr-aortic | Not yet recruiting | Muscle strength; function and gait | Not given |
| Phase 3 randomised controlled trial; 500 participants | TLC599 | Corticosteroid (slow release) | Intr-aortic | Recruiting | Pain (WOMAC) | Function |
| Phase 3 randomised controlled trial; 238 participants | EP-104IAR | Corticosteroid (slow release) | Intr-aortic | Not yet recruiting | Pain (WOMAC) | Function |
| Phase 3 randomised controlled trial; 40 participants | LRX712 | Not disclosed; pro-regenerative | Intr-aortic | Not yet recruiting | Structure (sodium cartilage content by MRI); Pharmacokinetics | |
| Phase 4 randomised controlled trial; 120 participants | Colchicine | Anti-inflammatory; precise mechanism disputed | Oral | Recruiting | Pain (visual analogue scale) | Function |
| Randomised controlled trial; 200 participants | Methotrexate | Immunosuppressant (folate antagonist) | Oral | Recruiting | Synovitis (MRI); pain (visual analogue scale) | Function |
| Randomised controlled trial; 120 participants | Methotrexate | Immunosuppressant (folate antagonist) | Oral | Not yet recruiting | Pain (visual analogue scale) | Function |
| Phase 3 randomised controlled trial; 164 participants | Resveratrol | Anti-ageing or anti-inflammatory (multiple proposed mechanisms of action) | Oral | Recruiting | Pain (numeric rating scale) | Function |
| Phase 1 open-label trial; 24 participants | FX201 | Interleukin-1 receptor antagonist gene therapy | Intr-aortic | Recruiting | Safety | Biodistribution |
| Phase 1 open label; 9 participants | ZC-001 | Interleukin-1 receptor antagonist | Intr-aortic | Recruiting | Safety | Not given |
| Phase 2 crossover randomised controlled trial; 100 participants | Adalimumab | Anti-tumour necrosis factor | Subcutaneous | Recruiting | OAIRF/OMERACT response | Pain; function |
| Phase 2 randomised controlled trial; 928 participants | GLPG13972 | ADAMTS-5 inhibitor | Oral | Not yet recruiting | Structure (cartilage thickness by MRI); Other structure; function and pain | |

Data taken from Clinicaltrials.gov on July 24, 2020. *Trial terminated due to COVID-19.

Table 2: Registered active drug trials in osteoarthritis
cartilage defects spontaneously regress over time.\textsuperscript{96} Regression of osteoarthritis, as measured by Kellgren and Lawrence x-ray score during a 14-year period, has been documented in the Chingford Women’s cohort,\textsuperscript{97} and preclinical studies show evidence of intrinsic repair of focal cartilage defects in a mouse strain (genetic) and age-dependent manner.\textsuperscript{98,99}

Load-altering procedures

The best clinical evidence of intrinsic cartilage repair in individuals with osteoarthritis comes from open-label studies of joint distraction. The largest study to date involved 20 patients. Applying a distraction frame for 6 weeks across the osteoarthritis knee joint resulted in an impressive clinical response (reduced pain and improved function assessed by the Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC]) and regrowth of tissue that resembled articular cartilage by MRI at 1 year and 2 years.\textsuperscript{100,101} Extended follow-up of this cohort showed that trial participants were less likely than a disease-matched osteoarthritis population to undergo joint replacement surgery.\textsuperscript{102} Similar, albeit smaller, studies have been done by other groups.\textsuperscript{103} The procedure results in a reduction of compressive load through the joint and complete prevention of surface shear stress (ie, no joint flexion). These concepts fit well with observations in mice, in which immobilising the knee joint in a fully extended position prevents osteoarthritic changes and protects the mouse from osteoarthritis after joint destabilisation. Maintaining some compressive force is likely to be more effective than complete joint immobilisation because it promotes the release of matrix-bound chondroprotective growth factors, such as fibroblast growth factor (FGF) 2.\textsuperscript{104}

When the synovial fluid levels of candidate molecules were examined over the course of joint distraction, out of ten analytes examined, only two, FGF2 and TGF\textbeta (both pro-regenerative growth factors), predicted a good clinical response.\textsuperscript{105}

High tibial osteotomy, whereby a wedge of bone is removed from the top of the tibia (usually) to correct valgus–varus joint malalignment, is also associated with clinical improvement.\textsuperscript{106} Moreover, when studies have examined the cartilage macroscopically through arthroscopy, histologically, or by MRI, evidence of cartilage regeneration is observed in the now off-loaded part of the joint.\textsuperscript{107–108}

Intra-articular FGF18

Sperifermin is a truncated form of FGF18. The FGFs form a large family of pleiotropic growth factors implicated in a range of physiological and pathological processes, including embryonic development, tissue repair, and cancer.\textsuperscript{109} Whereas FGF2 is promiscuous, binding to all four FGF receptors (FGFRs), FGF18 is thought to be more selective for FGFR3, which is the chondroprotective FGFR in murine osteoarthritis studies.\textsuperscript{109–112} Of note, polymorphic variants in FGFR3 have been identified in two genome-wide association studies: a population study\textsuperscript{113} associating a polymorphic variant with articular cartilage thickness, and another study\textsuperscript{114} that identified it as an at-risk allele in osteoarthritis. The latter study also identified FGF18 as a candidate gene associated with osteoarthritis risk.\textsuperscript{115}

In 2014, a proof-of-concept study\textsuperscript{116} was reported in which 192 individuals with osteoarthritis were randomly assigned to receive three doses of intra-articular sprifermin (recombinant truncated form of FGF18) or placebo, with follow-up at 6 months and 12 months. The study failed to meet its primary endpoint (a difference in articular cartilage thickness in the central medial femoro-tibial compartment), but it did show delayed loss of cartilage overall and thickening in the lateral compartment.\textsuperscript{116} In 2019, the FORWARD trial,\textsuperscript{117} in which 549 participants received intra-articular sprifermin every 6 months or 12 months, or placebo, reported a significant increase in total femoro-tibial cartilage volume compared with placebo at 2-year follow-up, albeit without significant clinical improvement. In a recent post-hoc analysis\textsuperscript{118} of the original trial data (thus far reported in abstract form), sprifermin treatment showed a statistically significant clinical and structural improvement over among a subgroup of 161 patients who were defined as being at high risk of progression. Although these studies do not specifically show reversal of cartilage damage (ie, true repair), they do show that damage can be arrested and therefore indicate a structure-modifying osteoarthritis drug. Whether these drugs turn out to be true disease-modifying osteoarthritis drugs is not yet clear. The apparent discordance between structure and symptoms in osteoarthritis is discussed later in this Review.

Intra-articular Wnt inhibitor

Wnts are a complex family of cellular signalling molecules that direct a broad range of cellular responses, particularly regarding bone development. Wnts are activated upon mechanical stress of articular cartilage\textsuperscript{119–121} and are thought to drive the dedifferentiated chondrocyte phenotype, bone remodelling, and induction of catabolic enzymes seen in osteoarthritis.\textsuperscript{122–125} Canonical Wnt signalling involves stabilisation of the signalling molecule beta-catenin within the cell. Interfering with beta-catenin has shown conflicting outcomes in experimental osteoarthritis, indicating that this molecule is not readily amenable to therapeutic translation.\textsuperscript{122} Interfering with natural inhibitors of Wnt signalling in mice, such as Dkk1 and Dot11, reveals the disease-modifying potential of this pathway.\textsuperscript{123,124} SM04690 is a synthetic Wnt inhibitor with an undisclosed (unknown) primary mechanism of action that has shown success in murine models of osteoarthritis.\textsuperscript{125–127} A phase 1 study of a single intra-articular dose of SM04690 in 61 participants with moderate osteoarthritis showed acceptable safety, with exploratory clinical endpoints that showed a positive trend towards improvement in pain and joint space narrowing.\textsuperscript{128} A phase 2 study of 455 individuals with
In one study,215 participants were randomly assigned to presses repair (figure 1).

Targeting nerve growth factor to treat osteoarthritis pain

Nerve growth factor (NGF) has long been known to sensitise pain fibres and, in doing so, enhance the firing rate of nociceptors in response to mechanical and thermal stimuli. NGF is also known to be a neurotrophic factor, directing the growth of new nerves.134 The use of anti-NGF neutralising antibodies to inhibit osteoarthritis pain has been heralded as a huge breakthrough for osteoarthritis patients who have struggled for years with inadequate pain relief. Several biological drugs targeting NGF, all delivered systemically (intravenously or subcutaneously), have been tested in phase 2 studies, with a meta-analysis showing efficacy across the different studies.135 Two companies have now published phase 2–3 studies using NGF neutralising antibodies,136–138 with fasinumab and tanezumab showing efficacy in mouse experiments and for which therapeutic strategies are being tested in clinical trials, and red circles indicate putative pathways identified in mice that have not yet been tested in clinical studies. Solid lines represent those with proven efficacy in human studies, and dashed lines indicate where clinical study outcomes are not yet known. Arrows indicate promotion, and flat line-ends represent suppression. Question marks indicate where connection is speculative. Load-altering procedures include surgical joint distraction and wedge osteotomy to correct joint malalignment, which probably suppress mechanoflammation. Peripheral pain arises from joint pathology and might suppress tissue inflammation and enable tissue repair by preventing mechanical overload of the joint. Zip8 is a zinc transporter that controls protease regulation in chondrocytes. FGFR=fibroblast growth factor receptor. IL=interleukin. YAP=transcriptional coactivator Yap. TAZ=WW domain-containing transcription regulator protein 1 (Taz) pathway involves in cellular mechanotransduction.130 Genetic and pharmacological enhancement of this pathway protects joints from osteoarthritis after joint destabilisation,132 which might in part be due to it controlling the generation of chondroprogenitor cells arising from the synovium.131 The Yap–Taz pathway also reciprocally controls Tak1132 (strongly induced by cartilage injury), and this might be an important mechanism by which inflammation suppresses repair (figure 1).

www.thelancet.com/rheumatology Vol 2 October 2020 e639
human tissue also support the notion that cartilage is the principal source of NGF in the osteoarthritis joint. Using agnostic approaches, NGF was not regulated in the synovium of individuals with painful compared with non-painful osteoarthritis, and it was not found in bone marrow lesions from samples taken at the time of arthroplasty. NGF was found to be regulated in damaged articular cartilage in early microarray studies of osteoarthritis cartilage, and it defines one of seven subsets of chondrocytes identified by single-cell sequencing of human osteoarthritis cartilage. NGF is regulated by direct cartilage injury (mechanoflammation) in a TAK1-dependent manner, and it is tempting to speculate that damage to chondrocytes near the osteochondral junction is an important trigger for the NGF-driven neoinnervation of the articular cartilage that is seen late in both murine and human disease. Neoinnervation of this region also requires a permissive subchondral bone to support axonal extension. This neoinnervation has recently been shown to be dependent upon Netrin-1, secreted by osteoclasts during the course of murine osteoarthritis. An overall model for the development of pain in osteoarthritis has been proposed.

Conclusions
There are many reasons to be optimistic about new therapeutic developments in osteoarthritis. Although it is true that much of what has been learned in the past few years from clinical studies is what not to use in disease, these negative studies have been highly informative in reminding the medical community that osteoarthritis is distinct from inflammatory arthritides, such as rheumatoid arthritis. Research has shown that inflammation in osteoarthritis is nuanced and that classical immunomodulatory pathways are not good targets, but that there are several other inflammatory pathways awaiting clinical exploration, including those driven by direct mechanical injury of the cartilage (so-called mechanoflammation), complement, and mast cells.

The nature and role of inflammation in osteoarthritis pathogenesis thus remains unclear. Clarification is crucially important, not only so that we can develop appropriate targeted therapies for patients, but also to decide whether patients require stratification before treatment. There has been a popular move to try to phenotype patients, with a view to personalising their treatment to improve the efficacy of a given drug. However, these phenotypes currently lack cohesion; some are defined by clinical features (e.g., inflammatory osteoarthritis), and others by co-morbidity (e.g., metabolic osteoarthritis), precipitating factor (e.g., post-traumatic osteoarthritis), or anatomical site (e.g., hand osteoarthritis, hip osteoarthritis). There is little or no evidence that stratification by any of these features changes the response to treatment. Further carefully considered phenotypes that take into consideration molecular pathways are probably required. Large-scale molecular endotyping of patient samples is currently in its infancy, but will probably help.

Clinical successes point towards a focus on regenerative or anabolic pathways rather than inflammatory ones. This suggestion fits well with preclinical studies, although the reciprocal relationship between repair and inflammation in the chondrocyte suggests that targeting one will probably affect the other. Recent large genome-wide association studies in osteoarthritis also support the concept that osteoarthritis is a failure of repair. Several at-risk loci have been attributed to genes in the TGFβ and FGF pathways, and there is a notable absence of loci that predict the regulation of classical inflammatory genes. Newer targets identified by genome studies, including the retinoic acid pathway, also look promising.

NGF-targeting for pain relief is the target closest to being ready to use in osteoarthritis. Clinical success in late osteoarthritis indicates that analgesia occurs largely as a result of nociceptor desensitisation. It remains to be seen whether interfering with this pathway at earlier stages of the disease could affect the neoinnervation of the cartilage...
Examples emerging that might identify true disease-modifying osteoarthritis drugs of the future, such as those involving the YAP–TAZ pathway.

Finally, it is reassuring to conclude that, where there is overlap, research in surgical preclinical osteoarthritis models aligns well with findings in clinical trials (figure 2). This concordance provides valuable validation of the models and will help develop mutual trust between the different osteoarthritis research disciplines. It is increasingly difficult to claim that mouse osteoarthritis is fundamentally different to human osteoarthritis, or that post-traumatic osteoarthritis does not inform age-related disease in humans. Part of this reassurance has emerged through improved awareness of bias mitigation in clinical and preclinical studies."143 It is also partly due to the acceptance that osteoarthritis has disease-specific molecular targets. Regardless, this is an important time for osteoarthritis research, with tangible translational benefits within reach.

Declaration of interests
TLV’s lab is supported by the Centre for Osteoarthritis Pathogenesis, Versus Arthritis (grant numbers 20205 and 21621). I would like to thank Dr Elizabeth Thompson for help with figures.

Acknowledgments
TLV’s lab is supported by the Centre for Osteoarthritis Pathogenesis, Versus Arthritis (grant numbers 20205 and 21621). I would like to thank Dr Elizabeth Thompson for help with figures.

References
1. Oo WM, Yu SP-C, Daniel MS, Hunter DJ. Disease-modifying drugs in osteoarthritis: current understanding and future therapeutics. Expert Opin Emerg Drugs 2018; 23: 331–47.
2. Losina E, Paltiel AD, Weinstein AM, et al. Lifetime medical costs of knee osteoarthritis management in the United States: impact of extending indications for total knee arthroplasty. Arthritis Care Res (Hoboken) 2015; 67: 203–15.
3. Kluzek S, Sanchez-Santos MT, Leyland KM, et al. Painful knee but not hand osteoarthritis is an independent predictor of mortality over 23 years follow-up of a population-based cohort of middle-aged women. Ann Rheum Dis 2016; 75: 1749–56.
4. Neogi T. The epidemiology and impact of pain in osteoarthritis. Osteoarthritis Cartilage 2013; 21: 1145–53.
5. Hawker GA. Osteoarthritis is a serious disease. Clin Exp Rheumatol 2019; 37 (suppl 120): 1–6.
6. Brandt KD, Dieppe P, Radin EL. Commentary: is it useful to subset “primary” osteoarthritis? A critique based on evidence regarding the etiopathogenesis of osteoarthritis. Semin Arthritis Rheum 2009; 39: 81–95.
7. Quinn TM, Schmid P, Hunziker EB, Grodzinsky AJ. Proteoglycan deposition around chondrocytes in agarose culture: construction of a physical and biological interface for mechanotransduction in cartilage. Biochemistry 2002; 39: 27–37.
8. Kim YJ, Sah RL, Grodzinsky AJ, Plass AH, Sandy JD. Mechanical regulation of cartilage biosynthetic behavior: physical stimuli. Arch Biochem Biophys 1994; 311: 1–12.
9. Lee RB, Wilkins RJ, Razaz S, Urban JP. The effect of mechanical stress on cartilage energy metabolism. Biochim Biophys Acta 2002; 39: 133–43.
10. Li X, Han L, Nookaew I, et al. Stimulation of Piezo1 by mechanical stress in osteoarthritis: current understanding and future therapeutics. Expert Opin Emerg Drugs 2018; 23: 331–47.
11. Vincent T, Hermansson M, Bolton M, Wirtz R, Saklatvala J. Basic FGF mediates an immediate response of articular cartilage to mechanical injury. Proc Natl Acad Sci USA 2002; 99: 8259–64.
12. Ismail HM, Didegahoe A, Vincent TL, Saklatvala J. Rapid activation of transforming growth factor β-activated kinase 1 in chondrocytes by phosphorylation and K562-link polyubiquitination upon injury to animal articular cartilage. Arthritis Rheumatol 2017; 69: 565–75.

due to the neurotrophic functions of NGF, and to what extent this could prevent painful disease from developing. This type of strategy would need to be considered in the context of current safety concerns around the development of rapidly progressive osteoarthritis, which remains a real concern. Other molecules that appear to have a role in the neoinervation of the osteochondral junction in osteoarthritis models include Netrin-1,152 a molecule secreted by osteoclasts that guides axonal growth through the subchondral bone. Blocking bone remodelling with a bisphosphonate early in murine osteoarthritis development appears to block pain without affecting structural disease, according well with clinical studies in osteoarthritis in which bisphosphonates are not disease-modifying when given in established disease.15A1.157

One major outstanding issue remains the apparent discordance between structural and symptomatic disease, which raises questions about whether validated drugs need to be able to, or indeed could ever, target both. Whether different joint pathologies give rise to different types of symptoms at different stages of disease is currently unknown, as is the relative contribution of factors that drive central sensitisation of pain. Of the few examples available at this stage, cartilage structure-modifying drugs (eg, sprifermin) mainly arrest disease progression rather than regenerating the cartilage, so perhaps symptoms could not be expected to reverse. Where structural damage appears to reverse (eg, after joint distraction), symptoms also appear to improve (albeit with no placebo control). Targeting pain alone is unlikely to improve structure in the short term and might worsen damage through mechanical overuse. In preclinical models, there tends to be better accordance between structural damage and pain-like behaviour;110 with some clear
dskeletal damage and pain

Search strategy and selection criteria
This is a narrative Review based on clinical trials done in hand and knee or hip osteoarthritis by searching PubMed with the terms “Phase” with “Trial” and “Osteoarthritis” in the title from Jan 1, 2012, to July 31, 2019. Further information was sought through Clinicaltrials.gov, by searching for “osteoarthritis” studies in which the intervention was “drug”. Preclinical studies were interrogated through Skeletonvis.ncl.ac.uk. This Review is not intended to be a comprehensive review of all clinical trials in osteoarthritis or all pathways identified through murine studies. Rather, its intention is to focus on those targets for which there is overlap between murine and human studies. Additionally, the Review highlights a few emerging pathways that have strong preclinical evidence for a role in pathogenesis and which could be amenable to clinical targeting. Inevitably, an exercise of this sort reflects the author’s personal views on pathogenesis, based on 20 years of working with preclinical surgical models, human tissue, and patients with osteoarthritis.
72: Pain Ther 2019; 8: 2019–2017.
73: Prog Natl Acad Sci USA 2015; 112: 9424–29.
74: Proc Natl Acad Sci USA 2015; 112: 9424–29.
75: Ann Rheum Dis 2013; 72: 300–04.
76: Radiat Med 2019; 10: 4881.
77: Rheumatology (Oxford) 2012; 51: 1931–41.
78: Ann Intern Med 2018; 168: 1056–69.
79: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
80: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
81: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
82: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
83: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
84: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
85: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
86: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
87: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
88: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
89: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
90: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
91: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
92: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
93: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
94: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
95: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
96: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
97: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
98: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
99: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
100: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
101: Arthritis Care Res (Hoboken) 2018; 70: 1120–25.
Stimulation-induced cartilage degradation does not depend on the NLRP3 inflammasome in human osteoarthritic mice and models. Arthritis Rheumatol 2012; 64: 1972–81.

Vincent TL. IL-1 in osteoarthritis: time for a critical review of the literature. F1000 Res 2019; 8: 1–8.

Ryu J-I, Yang S, Shin C, Rhee J, Chun C-H, Chun J-S. Interleukin-6 plays an essential role in hyposia-inducible factor 2α-induced experimental osteoarthritic cartilage destruction in mice. Arthritis Rheumatol 2011; 63: 2732–43.

de Hooge ASK, van de Loo FJ, Brenink MB, Arrzt OF, de Hooge P, van den Berg WB. Male IL-6 gene knock out mice developed more advanced osteoarthritis upon aging. Osteoarthrits Cartilage 2005; 13: 66–73.

Latoure A, Cherifi C, Maillot J, et al. Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis. Ann Rheum Dis 2017; 76: 748–55.

Glasson SS, Asker W, Sheppard B, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005; 434: 644–48.

Ismail HM, Yanaizkino K, Vincent TL, Nagase H, Troebel L, Skałkawla J. Interleukin-1α acts via the JNK-2 signaling pathway to induce aggrecan degradation by human chondrocytes. Arthritis Rheumatol 2015; 67: 1826–36.

Song RH, Tortorella MD, Malfait AM, et al. Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheumatol 2007; 56: 751–85.

Larkin J, Lohr T, Elefante L, et al. The highs and lows of translational drug development: antibody-mediated inhibition of ADAMTS-5 for osteoarthritis disease modification. Osteoarthrits Cartilage 2014; 22: 5481–83.

Decks HM, Hatch JD, Roberge MD, et al. A safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) study with increasing oral doses of GLPG1972 administered daily for 29 days in a murine model of osteoarthritis. J Pathol 2018; 25: 351–53.

Vincent T, Malfait AM. Time to be positive about negative data? Osteoarthritis and cartilage/OARS. Osteoarthritis Research Society 2017; 25: 531–53.

Virgili F, Calin A, Arnett FM, et al. Involvement of alarmins S100A8 and S100A9 in the regulation of joint tissues. Arthritis Rheum 2015; 67: 9165–71.

Castaño-Betancourt MC, Evans DS, Ramos YFM, et al. Novel genetic variants for cartilage thickness and hip osteoarthritis. PLoS Genet 2016; 12: e1006260.

Zengini E, Hatzikoutoulas K, Tschampauszki I, et al. Genome-wide analyses using UK Biobank data provide insights into the genetic architecture of osteoarthritis. Nat Genet 2018; 50: 549–58.

Bratus-Neuechwander A, Castro-Giner F, Frank-Bertoncini M, et al. Pain-associated transcriptome changes in synovium of knee osteoarthritis patients. Genes (Basel) 2018; 9: 138.

Ritter SY, Subhaiaia R, Belel G, et al. Proteomic analysis of synovial fluid from the osteoarthritic knee: comparison with transcriptome analyses of joint tissues. Arthritis Rheum 2013; 65: 981–92.

Buckley MG, Gallagher PJ, Walls AF. Mast cell subpopulations in the synovial tissue of patients with osteoarthritis: selective increase in numbers of tryptase-positive, chymase-negative mast cells. J Pathol 1998; 186: 67–74.

Nasi S, Ea H-K, Chobaz V, van Lent P, Liotet F, So A, et al. Dispensable role of myeloid differentiation primary response gene 88 (MyD88) and MyD88-dependent toll-like receptors (TLRs) in a murine model of osteoarthritis. Joint Bone Spine 2014; 81: 320–24.

Nasi S, Ea H-K, So A, Busso N. Revisiting the role of interleukin-1 pathway in osteoarthritis: interleukin-1α and -1β, and NLRP1 inflammasome are not involved in the pathological features of the murine menisectomy model of osteoarthritis. Front Pharmacol 2017; 8: 282.

van Lent PLEM, Blom AB, Schellerben RFP, et al. Active involvement of alarmin S100A8 and S100A9 in the regulation of synovial activation and joint destruction during mouse and human osteoarthritis. Arthritis Rheum 2012; 64: 1466–76.

Vincent T, Malfait AM. Time to be positive about negative data? Osteoarthritis and cartilage/OARS. Osteoarthritis Research Society 2017; 25: 531–53.

Vincent TL. Mechanoflammation in osteoarthritis pathogenesis. Semin Arthritis Rheum 2019; 49: 536–38.

Gruber J, Vincent TL, Hermannsson M, Bolton M, Wait R, Skałkawla J. Induction of interleukin-1β in osteoarthritis is mediated by endocytosis and extracellular matrix (ECM) remodeling. Arthritis Rheum 2004; 50: 2539–46.

Wait FE, Ismail HM, Didangelo A, et al. Src and fibroblast growth factor 2 independently regulate signaling and gene expression induced by experimental injury to intact articular cartilage. Arthritis Rheum 2013; 65: 397–407.

Castaño-Betancourt MC, Evans DS, Ramos YFM, et al. Novel genetic variants for cartilage thickness and hip osteoarthritis. PLoS Genet 2016; 12: e1006260.

Yamamoto KO, Kow SK, Parker AE, et al. Low density lipoprotein receptor-related protein 1 (LRP1)-mediated endocytic clearance of a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4): functional differences of non-catalytic domains of ADAMTS-4 and ADAMTS-5 in LRPI binding. J Biol Chem 2014; 289: 6642–74.

Yamamoto K, Torebring L, Scibarra SB, et al. LRP-1-mediated endocytosis regulates extracellular activity of ADAMTS-5 in articular cartilage. PLOS J 2013; 27: 21–21.

Kim J-H, Jeon J, Shin M, et al. Regulation of the catalytic cascade in osteoarthritis by the zinc-ZIP8-MTF1 axis. Cell 2014; 156: 730–43.

Lee M, Won Y, Shin Y, Kim JH, Chun JS. Reciprocal activation of hyposia-inducible factor (HIF)-1α and the zinc-ZIP8-MTF1 axis amplifies catalytic signaling in osteoarthritis. Osteoarthrits Cartilage 2016; 24: 134–45.

Saito T, Fukai A, Malabue A, et al. Transcriptional regulation of endochondral ossification by HIF1α-Zalp during skeletal growth and osteoarthritis development. Nat Med 2010; 16: 678–86.
95 Buchanan WJ, William Hunter (1718–1783). Rheumatology (Oxford) 2003; 42: 1260–61.
96 Dell’Acce F, Vincent TL. Joint surface defects: clinical course and cellular response in spontaneous and experimental lesions. Eur Cell Mater 2010; 20: 210–17.
97 Leyland KM, Hart DJ, Javid MK, et al. The natural history of radiographic knee osteoarthritis: a fourteen-year population-based cohort study. Arthritis Rheum 2012; 64: 2243–51.
98 Eltawil NM, De Bari C, Achan P, Pitalis C, Dell’Acce F. A novel in vivo murine model of cartilage regeneration. Age and strain-dependent outcome after joint surface injury. Osteoarthritis Cartilage 2009; 17: 695–704.
99 Rai MF, Hashimoto S, Johnson EE, et al. Heritability of articular cartilage regeneration and its association with ear wound healing in mice. Arthritis Rheum 2012; 64: 2300–10.
100 Wiegant K, van Roermund PM, Interna F, et al. Sustained clinical and radiographic improvement after joint distraction in the treatment of severe knee osteoarthritis. Osteoarthritis Cartilage 2013; 21: 1660–67.
101 Interna F, Van Roermund PM, Marijnissen ACA, et al. Tissue structure modification in knee osteoarthritis by use of joint distraction: an open 1-year pilot study. Ann Rheum Dis 2011; 70: 1441–46.
102 van der Woude JAD, Wiegant K, van Roermund PM, et al. Five-year follow-up of knee joint distraction: clinical benefit and cartilaginous tissue repair in an open uncontrolled prospective study. Cartilage 2017; 8: 261–71.
103 Mastbergen SC, Saris DBF, Lafiere FPJ. Functional articular cartilage repair: here, near, or is the best approach not yet clear? Nat Rev Rheumatol 2013; 9: 277–90.
104 Watt FE, Hamid B, Garriga C, et al. The molecular profile of synovial fluid changes upon joint distraction and is associated with clinical response in knee osteoarthritis. Osteoarthritis Cartilage 2020; 28: 324–33.
105 Tjernestrand BA, Eugnud N, Hagedstv BD. High tibial osteotomy: a seven-year clinical and radiographic follow-up. Clin Orthop Relat Res 1981; 166: 124–36.
106 Koshino T, Wada S, Ara Y, Saito T. Regeneration of degenerated articular cartilage after high tibial valgus osteotomy for medial compartmental osteoarthritis of the knee. Knee 2003; 10: 229–36.
107 Parker DA, Beatty KT, Giuffre B, Scholes CJ, Coolican MRJ. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 2009; 8: 235–53.
108 Valverde-Franco G, Binette JS, Li W, et al. Defects in articular cartilage metabolism and early arthritis in fibroblast growth factor receptor 3 deficient mice. Hum Mol Genet 2006; 15: 1783–92.
109 Tang J, Su N, Zhou S, et al. Fibroblast growth factor receptor 3 inhibits osteoarthritis progression in the knee joints of adult mice. Arthritis Rheumatol 2016; 68: 2432–43.
110 Xu W, Xie Y, Wang Q, et al. A novel fibroblast growth factor receptor 1 inhibitor protects against cartilage degradation in a murine model of osteoarthritis. Sci Rep 2016; 6: 24042.
111 Tschmaizoud I, Hatzikotoulas K, Southam L, et al. Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data. Nat Genet 2019; 51: 230–36.
112 Lohmander LS, Heliot S, Dreher D, et al. Intraarticular sparifloxin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 2014; 66: 1820–31.
113 Hochberg MC, Guermazi A, Guerhi H, et al. Effect of intra-articular sparifloxin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis: the FORWARD randomized clinical trial. JAMA 2019; 322: 1360–70.
114 Guhring H, Kraines J, Moreau F, et al. OP0010 cartilage thickness modification with sparifloxin in knee osteoarthritis patients translates into symptomatic improvement over placebo in patients at risk of further structural and symptomatic progression: post-hoc analysis of the phase II FORWARD trial. Ann Rheum Dis 2019; 78 (suppl 2): 70–71.
115 Dell’Acce F, De Bari C, Eltawil NM, Vanhummeleen P, Pitalis C. Identification of the molecular response of articular cartilage to injury, by microarray screening: Wnt-16 expression and signaling after injury and in osteoarthritis. Arthritis Rheum 2008; 58: 1430–41.
116 Dell’Acce F, De Bari C, El Tawil NMF, et al. Activation of WNT and BMP signaling in adult human articular cartilage following joint distraction and mechanical injury. Arthritis Rheum 2008; 6: R139.
117 Corr M. Wnt-beta-catenin signaling in the pathogenesis of osteoarthritis. Nat Clin Pract Rheumatol 2008; 4: 550–56.
118 Yasuhara R, Ohya Y, Tsuda T, et al. Roles of beta-catenin signaling in phenotypic expression and proliferation of articular cartilage superficial zone cells. Lab Invest 2013; 91: 1739–52.
119 Yuasa T, Kondo N, Yasuhara R, et al. Transient activation of Wnt/ beta-catenin signaling induces abnormal growth plate closure and articular cartilage thickening in postnatal mice. Am J Pathol 2009; 175: 1993–2003.
120 Kawaguchi H. Regulation of osteoarthritis development by Wnt-beta-catenin signaling through the endochondral ossification process. J Bone Miner Res 2009; 24: 8–11.
121 Funck-Brentano T, Bouazzou W, Marty C, Geoffrey Y, Hay E. Cohen-Solal M. Dkk-1-mediated inhibition of Wnt signaling in bone ameliorates osteoarthritis in mice. Arthritis Rheumatol 2014; 66: 3028–39.
122 Lories RJU, Peeters JB, Bakker A, et al. Articular cartilage and biomechanical properties of the long bones in Fzb-knockout mice. Arthritis Rheum 2007; 56: 4905–103.
123 Nalesso G, Thomas BL, Sherwood JD, et al. WNT6 antagonises excessive canonical WNT activation and protects cartilage in osteoarthritis. Ann Rheum Dis 2017; 76: 218–26.
124 Montenegro S, Cornellis FMM, Azzar-Lopez C, et al. DOT1L safeguards cartilage homeostasis and protects against osteoarthritis. Nat Commun 2017; 8: 15889–12.
125 Deshmukh V, Hu H, Barroga C, et al. A small-molecular inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee. Osteoarthritis Cartilage 2018; 26: 18–27.
126 Deshmukh V, O’Green AL, Bossard C, et al. Modulation of the Wnt pathway through inhibition of CLIK and DCKRIα by lorecivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment. Osteoarthritis Cartilage 2019; 27: 1347–60.
127 Yazici Y, McAlindon TE, Fleischmann R, et al. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis Cartilage 2017; 25: 1598–606.
128 Yazici Y, McAlindon TE, Gibosky A, et al. Lorecivint, a novel intra-articular CLIK/DCKRIα inhibitor and Wnt pathway modulator for treatment of knee osteoarthritis: a phase 2 randomized trial. Arthritis Rheumatol 2020; published online May 20. https://doi.org/10.1002/art.41315.
129 Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev 2014; 94: 1287–312.
130 Deng Y, Lu J, Li W, et al. Reciprocal inhibition of YAP/TAZ and NF-κB regulates osteoarthritic cartilage degradation. Nat Commun 2018; 9: 4564.
131 Roelofs AJ, Zupan J, Riemens AHK, et al. Joint morphogenic cells in the adult mammalian synovium. Nat Commun 2017; 8: 15040.
132 Denk F, Bennett DL, McMahon SB. Nerve growth factor and pain mechanisms. Annu Rev Neurosci 2017; 40: 307–25.
133 Yang S, Huang Y, Ye Z, Li L, Zhang Y. The efficacy of nerve growth factor antibody for the treatment of osteoarthritic pain and chronic low-back pain: a meta-analysis. Front Pharmacol 2020; published online June 30. https://doi.org/10.3389/fphar.2020.00817.
134 Dakin P, DiMartino SJ, Gao H, et al. The efficacy, tolerability and joint safety of fasinumab in osteoarthritis: a phase ii/iii double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheumatol 2020: expression 4: 307.
135 Tive L, Bello AE, Radin D, et al. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis of the knee or hip. J Pain Res 2019; 12: 975–95.
136 Schnitzer TJ, Easton R, Pang S, et al. Effect of tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis among patients with osteoarthritis of the hip or knee: a randomized clinical trial. JAMA 2019; 322: 37–48.
139 Watt FE, Blauwet MB, Fakhoury A, Jacobs H, Smulders R, Lane NE. Tropomyosin-related kinase A (TrkA) inhibition for the treatment of painful knee osteoarthritis: results from a randomized controlled phase 2a trial. *Osteoarthritis Cartilage* 2019; 27: 1590–98.

140 Krupa E, Jiang G-L, Jan C. Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study. *Osteoarthritis Cartilage* 2019; 27: 1599–607.

141 Inglis JJ, McNamee KE, Chia S-L, et al. Regulation of pain sensitivity in experimental osteoarthritis by the endogenous peripheral opioid system. *Arthritis Rheum* 2008; 58: 3110–19.

142 von Loga IS, El-Turabi A, Jostins L, et al. Active immunisation targeting nerve growth factor attenuates chronic pain behaviour in murine osteoarthritis. *Ann Rheum Dis* 2019; 78: 672–75.

143 Knights CB, Gentry C, Bevan S. Partial medial meniscectomy produces osteoarthritis pain-related behaviour in female C57BL/6 mice. *Pain* 2012; 153: 281–92.

144 LaBrancie TP, Bendele AM, Omura BC, et al. Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model. *Ann Rheum Dis* 2017; 76: 295–302.

145 McNamee KE, Burleigh A, Gompels LL, et al. Treatment of murine osteoarthritis with TrkAd5 reveals a pivotal role for nerve growth factor in non-inflammatory joint pain. *Pain* 2010; 149: 386–92.

146 Driscoll C, Chanalaris A, Knights C, et al. Nociceptive sensitizers are regulated in damaged joint tissues, including articular cartilage, when osteoarthritic mice display pain behavior. *Arthritis Rheumatol* 2016; 68: 857–67.

147 Kuttapiya A, Assi L, Laing K, et al. Microarray analysis of bone marrow lesions in osteoarthritis demonstrates upregulation of genes implicated in osteochondral turnover, neurogenesis and inflammation. *Ann Rheum Dis* 2017; 76: 1764–73.

148 Sato T, Konorn K, Yamasaki S, et al. Comparative analysis of gene expression profiles in intact and damaged regions of human osteoarthritic cartilage. *Arthritis Rheum* 2006; 54: 808–17.

149 Ji Q, Zheng Y, Zhang G, et al. Single-cell RNA-seq analysis reveals the progression of human osteoarthritis. *Ann Rheum Dis* 2019; 78: 300–10.

150 Obeidat AM, Miller RE, Miller RJ, Malfait AM. The nociceptive innervation of the normal and osteoarthritic mouse knee. *Osteoarthritis Cartilage* 2019; 27: 1669–79.

151 Walsh DA, McWilliams DF, Turley MJ, et al. Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. *Rheumatology (Oxford)* 2010; 49: 1852–61.

152 Zhu S, Zhu J, Zhen G, et al. Subchondral bone osteoclasts induce sensory innervation and osteoarthritis pain. *J Clin Invest* 2019; 129: 1076–93.

153 Vincent TL. Peripheral pain mechanisms in osteoarthritis. *Pain* 2020; 161: 5138–46.

154 Strykarsdottir U, Lund SH, Thorleifsson G, et al. Meta-analysis of Icelandic and UK data sets identifies missense variants in SMO, I111, COL11A1 and 13 more new loci associated with osteoarthritis. *Nat Genet* 2018; 50: 1681–87.

155 Jonsson H. Following the genetic clues towards treatment of hand OA. *Nat Rev Rheumatol* 2018; 14: 503–04.

156 Vaysbrot EE, Osani MC, Musetti MC, McAlindon TE, Bannuru RR. Are bisphosphonates efficacious in knee osteoarthritis? A meta-analysis of randomized controlled trials. *Osteoarthritis Cartilage* 2018; 26: 154–64.

157 Xing RL, Zhao LR, Wang PM. Bisphosphonates therapy for osteoarthritis: a meta-analysis of randomized controlled trials. *Springerplus* 2016; 5: 1704.

158 van der Worp HB, Howells DW, Sena ES, et al. Can animal models of disease reliably inform human studies? *PLoS Med* 2010; 7: e1000245.

© 2020 Elsevier Ltd. All rights reserved.